MIGRA-Therapeutics

Migra Therapeutics is a biopharmaceutical company focused on developing innovative drug delivery platforms and targeted therapies for advanced and drug-resistant solid tumors. Founded in 2018 as a spin-off from Emory University, the company utilizes a proprietary stroma-penetrating nanoparticle technology based on hyaluronic acid to overcome the dense physical barriers of the tumor microenvironment. Their lead program, MIGRA-NP01, is a nanoparticle-encapsulated formulation of SN-38 designed for the treatment of pancreatic cancer. Additionally, the company is developing the MIGRA-Cell platform to enhance the delivery and infiltration of CAR-T and NK cell therapies into solid tumors by targeting receptors such as CD44 and uPAR.